Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Completed · Phase 2 · NCT02467270

Conditions: Myeloid Leukemia, Chronic, Chronic Phase

Research payments reported, 2025: $71,390
U.S. investigators named: 5
Sites paid: 5
Planned or actual enrollment: 283

About the trial

Sponsor: Takeda
Tested: Ponatinib (drug)
Dates: Started 2015-07-13; completion 2025-04-23
Results posted: Yes

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.

From ClinicalTrials.gov, last updated 2026-03-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $71,390 in research payments for this study in 2025 (25 payments).

Products named: Iclusig

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Cleveland Clinic, OH $18,783
Ut MD Anderson Cancer Center $15,128
Unehealth $14,856
Karmanos Cancer Center, MI $14,295
Hackensack University Medical Center, NJ $8,328

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it